Evotec SE ADR (EVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evotec SE ADR (EVO) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.56 Million) by net assets ($800.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evotec SE ADR - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Evotec SE ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EVO total liabilities for a breakdown of total debt and financial obligations.
Evotec SE ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Energy Resources of Australia Ltd
AU:ERA
|
0.087x |
|
Isras Investment Company Ltd
TA:ISRS
|
0.013x |
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
-0.112x |
|
China Union Holdings Ltd
SHE:000036
|
-0.005x |
|
Arcos Dorados Holdings Inc
NYSE:ARCO
|
0.142x |
|
Fujian Septwolves Industry Co Ltd
SHE:002029
|
0.002x |
|
Teladoc Inc
NYSE:TDOC
|
0.071x |
|
Shanghai Zhezhong Construction Co Ltd
SHE:002346
|
0.039x |
Annual Cash Flow Conversion Efficiency for Evotec SE ADR (2003–2024)
The table below shows the annual cash flow conversion efficiency of Evotec SE ADR from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see EVO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $952.52 Million | $18.22 Million | 0.019x | -36.90% |
| 2023-12-31 | $1.12 Billion | $33.95 Million | 0.030x | -82.51% |
| 2022-12-31 | $1.19 Billion | $205.81 Million | 0.173x | +95.39% |
| 2021-12-31 | $1.38 Billion | $122.24 Million | 0.089x | +75.86% |
| 2020-12-31 | $886.41 Million | $44.72 Million | 0.050x | -36.01% |
| 2019-12-31 | $535.47 Million | $42.22 Million | 0.079x | -78.56% |
| 2018-12-31 | $424.88 Million | $156.24 Million | 0.368x | +1026.64% |
| 2017-12-31 | $331.75 Million | $10.83 Million | 0.033x | -89.63% |
| 2016-12-31 | $213.94 Million | $67.36 Million | 0.315x | +276.39% |
| 2015-12-31 | $187.09 Million | $15.65 Million | 0.084x | +448.94% |
| 2014-12-31 | $158.38 Million | $-3.80 Million | -0.024x | -157.25% |
| 2013-12-31 | $158.97 Million | $6.66 Million | 0.042x | -46.57% |
| 2012-12-31 | $152.55 Million | $11.96 Million | 0.078x | +13.75% |
| 2011-12-31 | $147.25 Million | $10.15 Million | 0.069x | +916.62% |
| 2010-12-31 | $132.64 Million | $899.00K | 0.007x | +103.46% |
| 2009-12-31 | $111.49 Million | $-21.85 Million | -0.196x | +28.84% |
| 2008-12-31 | $149.86 Million | $-41.28 Million | -0.275x | -48.33% |
| 2007-12-31 | $170.55 Million | $-31.67 Million | -0.186x | -176.14% |
| 2006-12-31 | $137.18 Million | $-9.22 Million | -0.067x | -367.85% |
| 2005-12-31 | $148.67 Million | $-2.14 Million | -0.014x | +95.23% |
| 2004-12-31 | $61.73 Million | $-18.60 Million | -0.301x | +22.58% |
| 2003-12-31 | $36.03 Million | $-14.02 Million | -0.389x | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more